glp-1 dose for diabetes receptor agonists are transforming care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are GLP-1 medications are becoming one

Peptides 137:170481 Marafini I, Zorzi F, Codazza S, Pallone F, Monteleone G (2013) TGF-beta signaling manipulation as potential therapy for IBD

doi: 10.1016/j.metabol.2021.154886 118 SkjaerbaekCFrystykJOrskovHKissmeyer-NielsenPJensenMBLaurbergSet al

Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, et al

Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement

5 Conclusions Despite increased healthcare budgets and improved quality of scientific data resulting in the development of evidence-based guidelines and recommendations aimed at promoting better individual health outcomes, the prevalence of unhealthy lifestyles, chronic conditions, and environmental challenges continues to accelerate

BB: What are you excited about